ISEI

Isei is a biotechnology company focused on developing a novel class of therapies for autoimmune and inflammatory diseases. The company's proprietary Immuno-Selective Effector Interference (ISEI) platform is designed to selectively target and neutralize the specific immune effector cells driving disease, while sparing the rest of the immune system. Founded by the pioneers of CAR-macrophage technology, Isei aims to provide more precise and effective treatments than current broad-spectrum immunosuppressants. The company is currently in the pre-clinical stage, advancing a pipeline of candidates for various high-need immunological conditions. By focusing on the underlying cellular drivers of inflammation, Isei seeks to redefine the standard of care for patients with chronic immune-mediated disorders.